PRESS RELEASE : EVOTEC SE REPORTS RESULTS FOR THE FIRST QUARTER 2021 AND PROVIDES CORPORATE UPDATE

DGAP-News: Evotec SE / Key word(s): Quarter Results/Quarterly / Interim Statement 
EVOTEC SE REPORTS RESULTS FOR THE FIRST QUARTER 2021 AND PROVIDES CORPORATE UPDATE 
2021-05-11 / 07:00 
The issuer is solely responsible for the content of this announcement. 
=---------------------------------------------------------------------------------------------------------------------- 
 
  . SUCCESSFUL START TO 2021 WITH STRONG STRATEGIC POSITION AND LONG-TERM STRATEGY: ACTION PLAN 2025 "THE DATA-DRIVEN R 
    &D AUTOBAHN TO CURES" 
  . GOOD PROGRESS WITHIN PRODUCT DEVELOPMENT PARTNERSHIPS AND CO-OWNED PORTFOLIO 
  . CONTINUED POSITIVE FINANCIAL PERFORMANCE; NO MATERIAL IMPACT THROUGH COVID-19 PANDEMIC 
Hamburg, Germany, 11 May 2021: 
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced the financial results and 
corporate updates for the first quarter 2021. 
HIGHLIGHTS 
RECORD LIKE-FOR-LIKE GROWTH OF BASE BUSINESS, STRONG BALANCE SHEET SUPPORTS ACCELERATING GROWTH 
  . Group revenues from contracts with customers increased by 11% to EUR 133.1 m (Q1 2020: EUR 119.4 m); Base business 
    growth of 28%, adjusted for the end of the Sanofi payment (since April 2020) and unfavourable fx effects 
  . EVT Execute revenue growth of 16% (11% adjusted for material recharges) to EUR 136.9 m (Q1 2020: EUR 118.2 m), EVT 
    Innovate revenues up 21% (20% adjusted for material recharges) to EUR 28.2 m (Q1 2020: EUR 23.3 m) 
  . Just - Evotec Biologics grew by more than 60% to EUR 9.7 m (Q1 2020: EUR 5.9 m) 
  . Like-for-like growth of adjusted Group EBITDA of 16%, despite higher R&D expenses; adjusted Group EBITDA of EUR 21.1 
    m (Q1 2020: EUR 30.0 m) affected by the anticipated end of the Sanofi payment (since April 2020) and unfavourable fx 
    effects 
  . Increased expenses for unpartnered R&D of EUR 14.9 m (Q1 2020: EUR 11.4 m) according to strategy 
  . Strong balance sheet with comfortable net debt position of EUR 56 m (equivalent to 0.6x EBITDA) provides significant 
    room for financing further growth; non-operating result benefits from fair value adjustment of the investment in 
    Exscientia Ltd. 
POSITIVE DEVELOPMENT WITH SEVERAL NEW AND EXPANDED PARTNERSHIPS; JUST - EVOTEC BIOLOGICS FURTHER GAINING MOMENTUM 
  . Multiple new and extended partnerships and alliances (e.g. with Annexon, Chinook Therapeutics, Related Sciences, 
    Takeda, The Mark Foundation, ...) 
      ? New development collaborations and INDiGO contracts signed (e.g. Riboscience, Step Pharma, ...) 
  . New iPSC- multi-year partnership with the Medical Center Hamburg Eppendorf ("UKE") 
  . Bristol Myers Squibb extend partnership in the field of targeted protein degradation 
  . Just - Evotec Biologics continuing on its success course: progress of the first J.POD^(R) facility in Redmond on 
    schedule; construction of first European "J.POD^(R) 2 EU" expected to start in H2 2021 
  . Partnership on oncology project EVT801 with Kazia Therapeutics (after period-end) 
  . New BRIDGEs ("beLAB2122" and "beLAB1407" (after period-end)) 
  . Projects entering into clinical phases (EVT894 (Chik-V); Immuno-oncology project A2a receptor antagonist 
    (Exscientia)) 
CORPORATE HIGHLIGHTS 
  . Implementation of next long-term strategic framework Action Plan 2025 "The data-driven R&D Autobahn to Cures" 
  . Chairman of the Supervisory Board of Evotec to retire from office effective as of the end of the Annual General 
    Meeting on 15 June 2021 (after period-end) 
GUIDANCE FOR FULL-YEAR 2021 CONFIRMED 
  . Business outlook for 2021 confirmed and mid-term targets given for the first time 
  . Group revenues expected to be in a range of EUR 550 - 570 m (EUR 565 - 585 m at constant exchange rates) (2020: EUR 500.9 
    m) 
  . Adjusted Group EBITDA expected to be in the range of EUR 105 - 120 m (EUR 115 - 130 m at constant exchange rates) 
    (2020: EUR 106.6 m) 
  . Unpartnered research and development expenses expected to be in a range of EUR 50 - 60 m (2020: EUR 46.4 m) 
INTRODUCTION OF MID-TERM GOALS ALIGNED WITH ACTION PLAN 2025 
  . Introduction of mid-term goals until 2025 at Capital Markets Day on 20 April 2021, targeting revenues growth to > EUR 
    1,000 m, adjusted EBITDA of >= EUR 300 m and unpartnered research and development expenses of > EUR 100 m 
Given current global insecurities surrounding the COVID-19 pandemic, a likely negative impact - though less pronounced 
than in 2020 - is already estimated within the guidance for revenues and adjusted EBITDA stated above. 
Key figures of consolidated income statement & segment information 
Evotec SE & subsidiaries - First quarter of 2021 
                                                                        Evotec Group Evotec Group 
                              EVT         EVT Intersegment Eliminations      Q1 2021      Q1 2020 
In TEUR                  Execute^4) Innovate^5) 
External revenues^1)      104,880      28,205                         -      133,085      119,402 
Intersegment revenues      32,033           -                  (32,033)            -            - 
Costs of revenue        (107,654)    (25,149)                    30,397    (102,406)     (86,130) 
Gross profit               29,259       3,056                   (1,636)       30,679       33,272 
Gross margin in %            21.4        10.8                         -         23.1         27.9 
 
R&D expenses^2)           (2,001)    (18,095)                     1,636     (18,460)     (15,056) 
SG&A expenses            (17,033)     (4,161)                         -     (21,194)     (17,254) 
Other operating             4,587      11,166                         -                    15,133 
income (expenses), net                                                        15,753 
Operating result           14,812     (8,034)                         -        6,778       16,095 
 
Adjusted EBITDA^3)         28,320     (7,215)                         -       21,105       30,002 

^1) Adjusted for negative exchange rate effects of EUR 6.0 m, Group revenues amount to EUR 139.1 m ^2) Of which unpartnered R&D expenses of EUR 14.9 m in Q1 2021 (Q1 2020: EUR 11.4 m) ^3) Before changes in contingent considerations, income from bargain purchase and excluding impairments on goodwill, other intangible and tangible assets as well as the total non-operating result ^4) Revenues from material recharges of EUR 5.6 m are allocated to EVT Execute as of Q1 2021 ^5) Revenues from material recharges of EUR 0.3 m are allocated to EVT Innovate as of Q1 2021 More detailed information and financial tables are available in our interim statement for the first quarter published on the Evotec website under the following link: https://www.evotec.com/en/invest/financial-publications Webcast/Conference Call

The Company is going to hold a conference call to discuss the results of the first quarter 2021 as well as to provide an update on its performance in the reporting period. The conference call will be held in English. Conference call details Date: Tuesday, 11 May 2021 Time: 02.00 pm CET (08.00 am EST, 01.00 pm GMT) From Germany: [phone] From France: [phone] From Italy: [phone] From UK: [phone] From USA: [phone] Access Code: 94660964#

A simultaneous slide presentation for participants dialling in via phone is available at https://www.webcast-eqs.com /evotec20210511/no-audio. Webcast details To join the audio webcast and to access the presentation slides you will find a link on our homepage www.evotec.com shortly before the event.

A replay of the conference call will be available for seven days and can be accessed from Germany by dialling [phone], from UK by dialling [phone] and from USA by dialling [phone].

The access code is 315614523#. The on-demand version of the webcast will be available on our website: https:// www.evotec.com/financial-reports.

ABOUT EVOTEC SE Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. We operate worldwide and our more than 3,700 employees provide the highest quality stand-alone and integrated drug discovery and development solutions. We cover all activities from target-to-clinic to meet the industry's need for innovation and efficiency in drug discovery and development (EVT Execute). The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuronal diseases, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases, fibrosis, rare diseases and women's health. On this basis, Evotec has built a broad and deep pipeline of more than 100 co-owned product opportunities at clinical, pre-clinical and discovery stages (EVT Innovate). Evotec has established multiple long-term alliances with partners including Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CHDI, Novartis, Novo Nordisk, Pfizer, Sanofi, Takeda, UCB and others. For additional information please go to www.evotec.com and follow us on Twitter @Evotec.

(MORE TO FOLLOW) Dow Jones Newswires

May 11, 2021 01:01 ET (05:01 GMT)